Too many U.S. patent examiners aren't "getting the memo" on how to apply recent court rulings on laws of nature and abstract ideas to patent applications covering drugs and diagnostics to software and financial management tools. Read More
In a move that may come as a surprise to few in the med-tech space, the U.S. Centers for Medicare & Medicaid Services has proposed to offer coverage with evidence development (CED) for leadless pacemakers, the newest technology in cardiac electrophysiology. Medtronic would seem to still have the lead in the leadless pacemaker business not only because the FDA has approved no other such devices, but also because the company's FDA-mandated post-approval study appears to be well suited to fulfill the requirements for a CED study. Read More
